Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 May;48(1):13-9.
doi: 10.1023/a:1006475312401.

The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases

Affiliations

The prognostic significance of vascular endothelial growth factor (VEGF C-1) immunoexpression in oligodendroglioma. An analysis of 91 cases

A Korshunov et al. J Neurooncol. 2000 May.

Abstract

Oligodendrogliomas continue to generate considerable difficulties in identifying prognostic factors, including single histopathological patterns. Among the latter, vascular productive changes have been intensively examined but the obtained results appear to be controversial. Numerous studies have revealed an indisputable importance of vascular endothelial growth factor (VEGF) immunoreactivity for malignant progression of astrocytomas but the data regarding oligodendrogliomas are heterogeneous. Ninety-one patients with oligodendroglioma were examined retrospectively for VECF immunoexpression. The results demonstrated significant preponderance of intracellular VEGF expression for WHO grade III tumors. Nevertheless, VEGF staining patterns correlated with both progression-free and overall survival only in univariate, but not in multivarite analysis. Only WHO tumor grade was found to be an independent prognostic factor for oligodendroglioma outcome. Therefore, it seems unlikely that VEGF immunohistochemistry will be of value in assessing individual oligodendroglioma prognosis, especially for determining of both progression-free and overall survival from histologically low-grade tumors.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Neuropathol Appl Neurobiol. 1998 Feb;24(1):21-8 - PubMed
    1. Cancer. 1995 Nov 15;76(10):1809-13 - PubMed
    1. J Neurosurg. 1992 Mar;76(3):428-34 - PubMed
    1. Neurosurgery. 1999 Dec;45(6):1279-91; discussion 191 - PubMed
    1. Am J Surg Pathol. 1998 Jul;22(7):816-26 - PubMed

MeSH terms

Substances

LinkOut - more resources